Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Advancis Will Go It Alone On Amoxicillin Pulsys

This article was originally published in The Pink Sheet Daily

Executive Summary

Firm will file NDA for pulsatile amoxicillin formulation in late 2006/early 2007 following positive Phase III results.

You may also be interested in...



Advancis Files NDA For Pulsatile Amoxicillin

The company does not rule out the possibility of copromoting the first once-daily formulation of the antibiotic as a way of expanding its sales force if Amoxicillin Pulsys is approved.

Advancis Files NDA For Pulsatile Amoxicillin

The company does not rule out the possibility of copromoting the first once-daily formulation of the antibiotic as a way of expanding its sales force if Amoxicillin Pulsys is approved.

Advancis Targeting Pharmacies In Effort To Energize Keflex 750 Sales

In sit-downs with retail pharmacy chains, Advancis is offering price incentives and arguing that the new cephalexin strength needs to be stocked because it has no generic equivalent.

Related Content

Topics

UsernamePublicRestriction

Register

PS064653

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel